Literature DB >> 17918040

Andrographolide inhibits human hepatoma-derived Hep3B cell growth through the activation of c-Jun N-terminal kinase.

Lili Ji1, Tianyu Liu, Jun Liu, Ying Chen, Zhengtao Wang.   

Abstract

Andrographolide (Andro) is a potentially anti-inflammatory diterpenoid lactone isolated from the traditional herbal medicine ANDROGRAPHIS PANICULATA, which has been effectively used for the treatment of infection, inflammation, cold, fever and diarrhea in China for centuries. In the current study, we found that Andro significantly decreased the number of surviving hepatoma-derived Hep3B cells in the MTT assay and induced cell apoptosis. Further study showed that Andro induced activation of mitogen-activated protein kinases (MAPKs) including p38 kinase, c-Jun N-terminal kinase (JNK) and extracellular signal-related kinases (ERK1/2), but had no significant effect on caspase-3, Bcl-xL and Bcl-2, which are apoptosis-related proteins. Moreover, inhibition of JNK activation partially rescued the toxic effect of Andro on Hep3B cells. Therefore, our results indicate that the JNK signaling pathway plays an important role in the toxic effect of Andro on Hep3B cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17918040     DOI: 10.1055/s-2007-990230

Source DB:  PubMed          Journal:  Planta Med        ISSN: 0032-0943            Impact factor:   3.352


  13 in total

1.  Terpenoids as potential chemopreventive and therapeutic agents in liver cancer.

Authors:  Roslin J Thoppil; Anupam Bishayee
Journal:  World J Hepatol       Date:  2011-09-27

2.  Andrographolide suppresses epithelial mesenchymal transition by inhibition of MAPK signalling pathway in lens epithelial cells.

Authors:  Forum Kayastha; Kaid Johar; Devarshi Gajjar; Anshul Arora; Hardik Madhu; Darshini Ganatra; Abhay Vasavada
Journal:  J Biosci       Date:  2015-06       Impact factor: 1.826

3.  siRNA Targeting Mcl-1 Potentiates the Anticancer Activity of Andrographolide Nanosuspensions via Apoptosis in Breast Cancer Cells.

Authors:  Supusson Pengnam; Purin Charoensuksai; Boon-Ek Yingyongnarongkul; Rungnapha Saeeng; Hasan Uludağ; Prasopchai Patrojanasophon; Praneet Opanasopit; Samarwadee Plianwong
Journal:  Pharmaceutics       Date:  2022-06-03       Impact factor: 6.525

4.  Isolation and identification of bioactive compounds in Andrographis paniculata (Chuanxinlian).

Authors:  Wen-Wan Chao; Bi-Fong Lin
Journal:  Chin Med       Date:  2010-05-13       Impact factor: 5.455

5.  Comparison of protein expression between human livers and the hepatic cell lines HepG2, Hep3B, and Huh7 using SWATH and MRM-HR proteomics: Focusing on drug-metabolizing enzymes.

Authors:  Jian Shi; Xinwen Wang; Lingyun Lyu; Hui Jiang; Hao-Jie Zhu
Journal:  Drug Metab Pharmacokinet       Date:  2018-03-10       Impact factor: 3.614

6.  HMPL-004 (Andrographis paniculata extract) prevents development of murine colitis by inhibiting T-cell proliferation and TH1/TH17 responses.

Authors:  Kathrin S Michelsen; Michelle H Wong; Brian Ko; Lisa S Thomas; Deepti Dhall; Stephan R Targan
Journal:  Inflamm Bowel Dis       Date:  2013-01       Impact factor: 5.325

7.  Andrographolide promotes vincristine-induced SK-NEP-1 tumor cell death via PI3K-AKT-p53 signaling pathway.

Authors:  Mingsheng Zhang; Enda Xue; Wei Shao
Journal:  Drug Des Devel Ther       Date:  2016-09-28       Impact factor: 4.162

8.  Increased reactive oxygen species levels cause ER stress and cytotoxicity in andrographolide treated colon cancer cells.

Authors:  Aditi Banerjee; Vivekjyoti Banerjee; Steven Czinn; Thomas Blanchard
Journal:  Oncotarget       Date:  2017-04-18

Review 9.  Andrographis paniculata (Burm. f.) Wall. ex Nees: a review of ethnobotany, phytochemistry, and pharmacology.

Authors:  Md Sanower Hossain; Zannat Urbi; Abubakar Sule; K M Hafizur Rahman
Journal:  ScientificWorldJournal       Date:  2014-12-24

10.  Andrographolide induces apoptosis of C6 glioma cells via the ERK-p53-caspase 7-PARP pathway.

Authors:  Shih-Hung Yang; Seu-Mei Wang; Jhih-Pu Syu; Ying Chen; Sheng-De Wang; Yu-Sen Peng; Meng-Fai Kuo; Hsiu-Ni Kung
Journal:  Biomed Res Int       Date:  2014-08-05       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.